Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease

European Journal of Neurology

Volumn 22, Issue 5, 2015, Pages 815-e56

  Ferreira, J J ^a   Rocha, J F ^b   Falcao A ^c   Santos, A ^b   Pinto, R ^b,d   Nunes, T ^b   Soares da Silva, P ^b,d,e  

^a INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d University of Porto   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

COMT inhibitor; Levodopa; Motor fluctuations; Opicapone; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; LEVODOPA; OPICAPONE; PLACEBO; ANTIPARKINSON AGENT; BENSERAZIDE; BENSERAZIDE, LEVODOPA DRUG COMBINATION; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DRUG COMBINATION; OXADIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENSERAZIDE; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; OXADIAZOLES; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84926410458     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12666     Document Type: Article

References (28)

1. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5-15.
2. Morgan JC, Sethi KD. Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs 2006; 11: 403-417.
3. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009; 16: 982-989.
4. Dingemanse J. Issues important for rational COMT inhibition. Neurology 2000; 55: S24-S27.
5. Palma PN, Bonifácio MJ, Almeida L, Soares-da-Silva P. Restoring dopamine levels. In: Simth HJ, Simons C, Sewell RDE, eds. Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies. Boca Raton, FL: CRC Press, 2007: 415-445.
6. Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983; 33: 278-282.
7. Gomes P, Soares-da-Silva P. Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 1999; 38: 1371-1380.
8. Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-588.
9. Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975; 17: 131-136.
10. Bonifácio MJ, Palma PN, Almeida L, Soares-Da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 2007; 13: 352-379.
11. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004; 62: S72-S81.
12. Lang AE, Lees A. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: S45-S51.
13. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004; 62: S39-S46.
14. Bet L, Bareggi SR, Pacei F, Bondiolotti G, Meola G, Schapira AH. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur J Neurol 2008; 15: 268-273.
15. Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002; 43: 201-207.
16. Kiss LE, Soares-Da-Silva P. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. J Med Chem 2014; 57: 8692-8717.
17. Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010; 53: 3396-3411.
18. Palma PN, Laszlo K, Soares-da-Silva P. Catechol-O-methyltransferase inhibitors: present problems and relevance of the new ones. In: Martinez A, Gil C, eds. Emerging Drugs and Targets for Parkinson's Disease. Cambridge: The Royal Society of Chemistry, 2013: 83-109.
19. Palma PN, Bonifácio MJ, Loureiro AI, Soares-da-Silva P. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstrate relative free energy calculations. J Comput Chem 2012; 33: 970-986.
20. Bonifacio MJ, Sutcliffe JS, Torrao L, Wright LC, Soares-da-Silva P. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology 2014; 77: 334-341.
21. Bonifácio MJ, Torrão L, Loureiro AI, Wright LC, Soares-da-Silva P. Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 2012; 18(S2): S125.
22. Almeida L, Rocha J-F, Falcão A, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 2013; 52: 139-151.
23. Rocha JF, Almeida L, Falcao A, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 2013; 76: 763-775.
24. Rocha JF, Falcao A, Santos A, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 2014; 70: 1059-1071.
25. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-1028.
26. Guy W. Assessment Manual for Psychopharmacology. Washington, DC: Department of Health Education and Welfare, 1976.
27. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
28. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23: 75-81.